Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Core Points - Genmab A/S is initiating a cash tender offer to acquire all outstanding common shares of Merus N.V. for $97.00 per share [1] - The offer is part of a transaction agreement dated September 29, 2025, between Genmab, its subsidiary, and Merus [1] - Merus's Board of Directors has recommended that shareholders accept the offer [2] Offer Details - The tender offer will expire at 5:00 p.m. New York City time on December 11, 2025, unless extended [3] - If conditions are met, a subsequent offering period will commence on the first business day following the expiration [3] - The offer is not subject to a financing condition but is subject to other conditions, including a minimum tender condition [4] Shareholder Information - Merus shareholders are advised to review the tender offer documents filed with the SEC before deciding to tender their shares [5] - These documents can be accessed for free on the SEC's website or through the information agent for the tender offer [5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics [6] - The company has a vision to transform the lives of patients with cancer and serious diseases through advanced antibody medicines by 2030 [6] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a global presence [7]